More than 14,000 women in England who have gone through the menopause could benefit from a new drug that reduces the risk of bone fractures. Abaloparatide – which is sold as Eladynos and made by Theramex – has been given the green light for NHS use by the National Institute for Health and Care Excellence (Nice). The pre-filled pen is injected into the skin at home once a day, bolstering bone density by stimulating the cells that make new bone.
Bone density starts to decline in the lead-up to the menopause because of a decrease in the levels of the female sex hormone oestrogen . The drug has been recommended for patients at a high risk of bone fractures, with Nice estimating that it could benefit more than 14,000 women who have gone through the menopause . Professor Jonathan Benger, chief medical officer and deputy chief executive of Nice, said: “The independent committee heard from patients about how debilitating osteoporosis can be and how it impacts all aspects of day-to-day life, such as not going out for a walk because they are fearful of falling and having a fracture.
Read Next 'I’m exhausted': the women waiting years for NHS gynaecological treatment “This can impair mental and physical health. Our focus is on enabling access to care that improves quality of life while offering value to the taxpayer. “Abaloparatide has been found by our independent committee to be clinically and cost effective at reducing the risk of fracture, giving people more independence .
